Kyoko Takahashi Lin
Lawyers
Filters
CureVac $450 million public offering
We advised CureVac on the equity offering
IHS Markit joint venture with CME Group
We are advising IHS Markit on its agreement with CME Group to combine their post-trade services into a new joint venture
Comcast subsidiary FreeWheel acquires BeeswaxIO
Davis Polk is advising FreeWheel, a subsidiary of Comcast Corporation, on its acquisition of BeeswaxIO Corporation. Financial terms of the deal were not disclosed.
FreeWheel, a Comcast…
BRP Group $258.1 million follow-on offering of common stock
Davis Polk advised BRP Group, Inc. on its $258.1 million follow-on offering of 8,750,000 shares of Class A common stock. The shares of Class A common stock are listed on the Nasdaq Global…
IHS Markit $44 billion merger with S&P Global
Davis Polk is advising IHS Markit on its all-stock merger with S&P Global that values IHS Markit at an enterprise value of $44 billion. Under the terms of the merger agreement, each…
Bertelsmann $2.175 billion acquisition of Simon & Schuster
Davis Polk is advising Bertelsmann on the $2.175 billion acquisition by its global trade book publishing group, Penguin Random House, of Simon & Schuster from ViacomCBS. The transaction…
Assurant acquisition of HYLA Mobile
Davis Polk is advising Assurant on its acquisition of mobile device trade-in innovator HYLA Mobile. The transaction is expected to close by the end of 2020, subject to regulatory and other…
Morgan Stanley $7 billion acquisition of Eaton Vance
Davis Polk is advising Morgan Stanley on its $7 billion acquisition of Eaton Vance Corp. The acquisition is subject to customary closing conditions and is expected to close in the second…
Pactiv Evergreen $574 million IPO
Davis Polk advised Pactiv Evergreen Inc. (formerly known as Reynolds Group Holdings Limited) on its $574 million initial public offering of 41,026,000 shares of common stock. The shares of…
Gilead Sciences $21 billion acquisition of Immunomedics
Davis Polk is advising Gilead Sciences, Inc. in its acquisition of Immunomedics, Inc. for $88.00 per share in cash. The transaction, which values Immunomedics at approximately $21 billion,…